Sinovac Biotech annouced that its first animal study of a vaccine against COVID19 showed good saftey results and efficcy on Rehusus Macaques monkeys.
For the study researchers developed a pilot scale production of a purified inactivated Sars cov2 vaccine candidate
The vaccine sarscov 2 specific neutralizing antibodies in mices rats and rhesus macaques.
These ntibodies neutalized 10 representative of sars cov2 strains.
Suggesting a possible broader neutralizing ability against cov2 strains.
Samples of 11 hospitalized patients were used in the study.
These included samples from China, Italy, Spain and UK.
These samples contained SARS-COV-2 strains that are widely scattered on the phylogenic tree.
Three immunizations using two different doses 3micrograms or 6micrograms per doser providedpartial or complete protection in Macaques against SARS-COV-2.
This is the first challenge study of its SARS-COV-2 vaccine candidate on animals.
The study proved that the vaccine candidate provides good saftey and complete protectt in Rhesus Macaques
The researches said that while this observation dosent currently prove PiCoVacc's ability to produce similar results in humans.
It shows that the candidate vaccine can induce a strong and potent immunity response.
Recently a team of researche from Los Alamos National Laboratory has founded 14 mutations to SARS-COV-2 virus.
The work involved analyzing the genomes of the virus founded in 6000 infected peole around the globe.
In January 2020 the company partned with leading research institutes to work on developing a vaccine against covid19. The company recived approval to comduct phase 1/2 studies on its inactivated vaccine candidate against COVID19.
Phase 1 trial included 144 healthy adults aged 18-59 years.
Comments
Post a Comment